Hyderabad, India

Prabhakar Divya

This inventor holds 1 USPTO granted patent. Top assignee: Natco Pharma Limited. Active years: 2026.


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Prabhakar Divya: Innovator in Pharmaceutical Chemistry

Introduction

Prabhakar Divya is a notable inventor based in Hyderabad, India. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative processes for drug preparation. His work is characterized by a commitment to enhancing the purity and efficacy of pharmaceutical compounds.

Latest Patents

Prabhakar holds a patent for the "Process for the preparation of high pure Eribulin and its Mesylate salt." This invention involves a sophisticated method for producing high-purity Eribulin and its mesylate salt, utilizing chiral acid addition salts of Eribulin. This advancement is crucial for improving the quality of this important cancer treatment drug.

Career Highlights

Prabhakar is currently employed at Natco Pharma Limited, a leading pharmaceutical company known for its focus on developing high-quality generic medications. His role at Natco Pharma has allowed him to apply his expertise in pharmaceutical processes and contribute to the company's innovative projects.

Collaborations

Throughout his career, Prabhakar has collaborated with talented professionals, including Srinivasu Kasa and Durga Prasad Konakanchi. These collaborations have fostered a productive environment for innovation and have led to significant advancements in their respective fields.

Conclusion

Prabhakar Divya's contributions to pharmaceutical chemistry, particularly through his patent on Eribulin, highlight his role as an innovator in the industry. His work continues to impact the development of effective cancer treatments, showcasing the importance of innovation in healthcare.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…